GSK plc: Director's Associate Transaction Notified
Ticker: GLAXF · Form: 6-K · Filed: Oct 30, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Oct 30, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: insider-filing, transaction-notification
Related Tickers: GSK
TL;DR
GSK director's wife involved in a transaction, filing shows.
AI Summary
GSK plc filed a Form 6-K on October 30, 2024, reporting a transaction notification regarding a person closely associated with a Director/PDMR. Lady Susan Symonds, a PCA of Sir Jonathan Symonds (Non-Executive Director), was involved in this transaction.
Why It Matters
This filing provides transparency into potential insider transactions, which can offer insights into the company's leadership's confidence in its stock.
Risk Assessment
Risk Level: low — This is a routine disclosure of a transaction by an individual closely associated with a director, not a significant operational or financial event.
Key Players & Entities
- GSK plc (company) — Registrant
- Lady Susan Symonds (person) — PCA of Sir Jonathan Symonds
- Sir Jonathan Symonds (person) — Non-Executive Director
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Who is the registrant?
The registrant is GSK plc.
What is the primary purpose of this filing?
The filing is a transaction notification regarding a PDMR/person closely associated with them.
Who is the specific individual mentioned in the transaction notification?
Lady Susan Symonds, who is a PCA (person closely associated) of Sir Jonathan Symonds.
What is Sir Jonathan Symonds' role at GSK plc?
Sir Jonathan Symonds is a Non-Executive Director at GSK plc.
Filing Stats: 390 words · 2 min read · ~1 pages · Grade level 15.3 · Accepted 2024-10-30 12:29:06
Filing Documents
- a2796k.htm (6-K) — 36KB
- 0001654954-24-013480.txt ( ) — 37KB
SIGNATURES
SIGNATURES     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: October 30, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc